2021 – EBF Cyberconnect Events:
Program of EBF Focus Workshop “Spotlight on (LBA/CBA & Automation) TECHNOLOGY” 20-21 May 2021
PDF renditions of the powerpoint presentations given at the Focus Workshop can be viewed and downloaded from this page. The program itself can be viewed and downloaded by clicking here
| Day 1 (times are CEST) | |||
| 12:30 | 12:45 | Coming online | |
| 12:45 | 13:00 | Getting started – Welcome Philip Timmerman – EBF |
|
| 13:00 | 14:30 | Session 1: Ligand binding assay technological innovation | |
| 13:00 | 13:10 | Introduction to the session by the session chair (Robert Nelson, Covance) | |
| 13:10 | 13:30 | Gregor Jordan, F. Hoffmann La Roche | |
| Experience in the use of S-PX imaging and analysis system for sensitive target engagement analysis | |||
| 13:30 | 13:50 | Christoph Bock, Abbvie | |
| Development of a high sensitivity, single-molecule based ligand binding assay for the detection of biomolecules in a regulated bioanalysis lab – Opportunities, Challenges and Limitations | |||
| 13:50 | 14:10 | John Chappell, Gyros | |
| Determining Binding Affinity and Kinetics using solution based Ligand binding assays | |||
| 14:10 | 14:30 | Q&A | |
| Including introduction to session 2 and the round tables | |||
| 15:00 | 16:50 | Session 2: Functional assays becoming ready for the toolbox of the regulated BA lab | |
| 15:00 | 15:10 | SHORT recap of introduction into the session 2 & round tables by session chair (Anna Laurén, Novo Nordisk) | |
| 15:10 | 15:30 | Henko Tadema, PRA-HS | |
| Flow cytometry: The pivotal use of flow cytometry in cell therapy development | |||
| 15:30 | 15:50 | Sion Lewis, UCB Pharma | |
| Flow cytometry: Evolution of the flow lab into the Bioanalytical world | |||
| 15:50 | 16:10 | Julian J. Freen-van Heeren, Sanquin | |
| Proof of principle for the use of the T cell ELIspot in clinical trial settings | |||
| 16:10 | 16:30 | Chiara Cazzin, on behalf of EBF | |
| Considerations for the context of use of qPCR application and validation in the BA laboratory” | |||
| 16:30 | 16:50 | Jessica Zheng Wang, AstraZeneca – Not released for publication (not released for publication) | |
| Development of a mechanism of action reflective and robust potency assay for a therapeutic antibody against alpha toxin using rabbit erythrocytes | |||
| 16:50 | 17:00 | Logistic break – break into small e-tables/rooms for Interactive round table discussions | |
| 17:00 | 18:15 | Session 2: Interactive round tables | |
| Theme: Who will grab “session-2 technologies”? and what makes sense or doesn’t from a regulatory perspective…. Outcome will be presented on day 2 and is input for the closing panel discussion |
|||
| 18:15 | Close breakout rooms | ||
| End of day 1 in plenary “see you tomorrow” Zoom session stays open to allow continued session or 1/1 interacttions |
|||
| 19:00 | Zoom closes | ||
| Day 2 (times are CEST) | |||
| 12:45 | 13:00 | Coming online | |
| 13:00 | 14:40 | Session 3: Business Strategies driving Automation or Automation driving Business Strategies? | |
| Session chair: Johannes Stanta, Freeline Therapeutics | |||
| 13:00 | 13:20 | Johannes Stanta, on behalf of the EBF (and session chair) – – Not released for publication (not released for publication) | |
| Blue Sky | |||
| 13:20 | 13:40 | John Smeraglia, UCB Pharma | |
| Role of automation in maximizing portfolio value – the future is now. | |||
| 13:40 | 14:00 | Nils Boehm, Abbvie | |
| Automation: Impact on operational workflows and information management | |||
| 14:00 | 14:20 | Katharina Lang, Novo Nordisk | |
| Fully paperless or less paper? A journey towards the paperless lab | |||
| 14:20 | 14:40 | Cecilia Arfvidsson, on behalf of the EBF | |
| Automation and the DI challenges | |||
| 14:40 | 15:00 | Break | |
| 15:00 | 16:40 | Session 4 – Overcoming challenges – Automation solutions delivering value (incl. pandemic inspired solutions) | |
| Session chair: Matthew Barfield, F. Hoffmann – La Roche | |||
| 15:00 | 15:20 | Animesh Shukla, AstraZeneca | |
| Benefits, Challenges and Solutions for Setting up Automation in a Regulated Lab: A Case Study | |||
| 15:20 | 15:40 | Scott Summerfield, GlaxoSmithKline | |
| Transitioning to an ‘automation-first’ culture in Bioanalysis – our learnings from the last 3 year | |||
| 15:40 | 16:00 | Steffan Svejgaard Petersen, Novo Nordisk | |
| How high-throughput COVID-19 analysis can shape the future of our laboratory automation | |||
| 16:00 | 16:20 | Michael Gröschl, Celerion | |
| Lab automation in pandemic times – how can robots ensure lab staff`s health and safety? | |||
| 16:20 | 16:40 | Q&A and discussion | |
| 16:40 | 17:00 | Short break | |
| 17:00 | 18:00 | Session 2 round table recap and close out panel discussion | |
| Feedback from day-1 round table Panel discussion and recommended next steps |
|||
| 18:00 | Adjourn | ||
| Meeting ends Zoom session stays open to allow continued session or 1/1 interacttions |
|||
| 19:00 | Zoom closes |
| Organising Committee: : Matthew Barfield (Roche), Anna Laurén (NovoNordisk), Robert Nelson (Covance), Johannes Stanta (Freeline Therapeutics) and Philip Timmerman (EBF) |
